DCGI approval

It is a topical solution that will cost Rs 1850 for a week’s treatment, and can reportedly help prevent amputation

The company informed that these tablets, to be marketed under brand name Favizen, will be manufactured with in-house API

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be…

A multi-centric, open label, two-arm randomized pivotal clinical trial was conducted in 30 eligible patients at four hospitals…